

# MetaStat Announces Positive Topline Results of a MetaSite Breast(TM) Prognostic Study in Invasive Breast Cancer

## This Study Independently Verifies Results of a Recently Published Study From Rohan et al., Using MetaStat's Fully Automated MetaSite Breast(TM) Test

BOSTON, MA -- (Marketwired) -- 09/23/15 -- MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company, today announced positive preliminary results from a study of MetaSite *Breast*<sup>TM</sup> in patients with ER-positive, HER2-negative early stage invasive breast cancer. The prognostic study met its prospectively defined primary endpoint. It demonstrated the MetaSite *Breast*<sup>TM</sup> Score is significantly and directly associated with increased risk of distant metastasis in ER-positive, HER2-negative invasive breast cancer for both high (>35 MetaSites) versus low (<12 MetaSites) MetaSite scores (OR = 3.4; 95%CI = 2.8-4.1; P=0.0002) as well as between intermediate (12-35 MetaSites) and low MetaSite scores (OR=3.24; 95%CI = 2.6-3.9; P=0.0006).

"Independent verification of these data at MetaStat's central laboratory using our fully automated MetaSite *Breast*<sup>TM</sup> assay is an important milestone for the company," said Douglas A. Hamilton, MetaStat's President and Chief Executive Officer. "We are encouraged by these results including the separation of the low and intermediate risk groups in addition to the low and high risk groups. We look forward to conducting additional clinical validation studies demonstrating the prognostic and chemo-predictive power of the MetaSite *Breast*<sup>TM</sup> test as we prepare for commercialization in 2016."

The MetaSite *Breast*<sup>TM</sup> Score predicted risk of distant metastasis in ER-positive, HER2-negative early stage invasive breast cancer independent of traditional clinical factors. MetaStat plans to submit complete data from this study for presentation at a future medical meeting.

### **About the Kaiser Permanente Cohort MetaSite Breast<sup>TM</sup> Prognostic Study**

The Kaiser Cohort MetaSite *Breast*<sup>TM</sup> clinical study is a prospectively defined case-controlled nested cohort of 3,760 patients with invasive ductal carcinoma of the breast diagnosed between 1980 and 2000 followed through 2010 from the Kaiser Permanente Northwest health care system. Case patients were women diagnosed with invasive breast cancer who subsequently developed distant metastasis. Of the 573 breast cancer tissue blocks received 481, representing 259 case-controlled pairs, were usable and included in the study.

### ***About MetaStat, Inc.***

MetaStat, Inc. (MTST) is a molecular diagnostic company that develops and commercializes tissue-based diagnostic tests for prediction of cancer metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, lung, colorectal and prostate cancers, where aggressive cancer is responsible for approximately 90% of all deaths. The company's driver-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the Mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite *Breast*<sup>™</sup> and MenaCalc<sup>™</sup> assays are designed to accurately stratify patients based on the aggressiveness of their tumor and risk the cancer will spread. MetaStat's testing platform improves treatment planning decisions by positively identifying patients at high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. The company is based in Boston, MA.

### ***Forward-Looking Statements***

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

Contact:

MetaStat

Rick Pierce

617-531-0874

[Rpierce@metastat.com](mailto:Rpierce@metastat.com)

Source: MetaStat, Inc.